Improving tannic-acid lipid nanoparticles to deliver an mRNA vaccine for melanoma
Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma
Researchers are developing improved nanoparticle carriers to deliver mRNA that helps the immune system recognize and attack melanoma.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11167871 on NIH RePORTER |
What this research studies
This project focuses on creating and refining tannic-acid lipid nanoparticles that can carry mRNA encoding melanoma antigens into immune cells called dendritic cells. The team will test different nanoparticle formulations in the lab and in animal melanoma models to see which best delivers the mRNA and triggers anti-tumor immune responses. Findings will guide selection of a lead formulation with the strongest anti-melanoma effects and the best safety profile. Successful lead formulations would then be positioned for further development toward human testing.
Who could benefit from this research
Good fit: When this line of work moves to clinical trials, ideal candidates would be people with melanoma—particularly those with tumors showing immune activity or with BRAF-related tumors—who are eligible for investigational vaccine trials.
Not a fit: People without melanoma, those with other cancer types, or patients who are medically unable to receive immune-based therapies would not be expected to benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to mRNA vaccines that better activate the immune system to control or eliminate melanoma.
How similar studies have performed: mRNA vaccines delivered by lipid nanoparticles have proven highly effective for infectious diseases and early cancer vaccine studies show promise, but applying tannic-acid lipid nanoparticle formulations to melanoma is a novel, preclinical approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Fenton, Owen S — Univ of North Carolina Chapel Hill
- Study coordinator: Fenton, Owen S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.